Navigation Links
Clarient to Present at Noble Financial's 5th Annual Equity Conference on Tuesday, June 9th
Date:6/3/2009

Presentation Scheduled for 11:35am EDT

ALISO VIEJO, Calif., June 3 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Ron Andrews, CEO and Vice Chairman, is scheduled to make an investor presentation at Noble Financial's 5th Annual Equity Conference at 11:35am EDT on Tuesday, June 9, 2009. The conference will be held at the Seminole Hard Rock Hotel and Casino in Hollywood, Florida on June 8-9, 2009.

A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.

About Clarient

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

    Press Contact:
    Kristy DelMuto
    Gregory FCA
    (610) 228-2118
    kristy@gregoryfca.com

    Investor Contact:
    Matt Clawson
    Allen & Caron Inc
    (949) 474-4300
    matt@allencaron.com


'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
2. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
3. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
4. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
5. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
6. Jim Agnello to Resign as Clarient Chief Financial Officer
7. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Clarient to Commercialize Novel Breast Cancer Profile
10. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 Four US ... evaluation today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ... California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... ETF Trends, market observers are growing more bullish on ... enact reforms to free cash held overseas for tax ...
(Date:2/26/2017)... ... ... Rob Lowe is a well recognized television personality, so it seems natural he would ... important to the American public and important to society at large. An upcoming episode ... the world for a few years. , The climate and how we relate to ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):